FDA Memo Previews Key COX-2/NSAID Advisory Committee Questions
This article was originally published in The Tan Sheet
Executive Summary
FDA advisory committee members will be asked to identify populations for whom COX-2 benefits outweigh risks during an upcoming meeting
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning